$100MSeries D, 22 July 2025
Funds a Phase IIb trial of AP01 and moving AP02 into Phase II.
- Amount
- $100M
- Stage
- Series D
- Announced
- 22 July 2025
- Lead
- Suvretta Capital
- Other investors
- SR One, Novo Holdings, Catalio Capital, T. Rowe Price
- Use of funds
- Funds a Phase IIb trial of AP01 and moving AP02 into Phase II.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Avalyn Pharma raises $100M Series D biospace.com
Avalyn Pharma raises $100M Series D daytraders.com